Cargando…
Real‐life effectiveness of MP‐AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy
INTRODUCTION: Most allergic rhinitis (AR) patients have moderate‐to‐severe, persistent disease. Meda Pharma's AzeFlu (MP‐AzeFlu) combines intranasal azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel formulation in a single device to treat AR. This prospective, noninterve...
Autores principales: | Kaulsay, Ranbir, Nguyen, Duc Tung, Kuhl, Hans Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247236/ https://www.ncbi.nlm.nih.gov/pubmed/30306729 http://dx.doi.org/10.1002/iid3.237 |
Ejemplares similares
-
MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020) -
Real-Life Effectiveness of MP-AzeFlu (Dymista(®)) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale
por: Stjärne, Pär, et al.
Publicado: (2023) -
Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020) -
MP‐AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children
por: Berger, W., et al.
Publicado: (2016) -
Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)